{"id":30144,"date":"2026-07-02T21:00:00","date_gmt":"2026-07-02T19:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=372d991c0f949e34e2a66ff3e5c3bed1"},"modified":"2026-07-02T21:00:00","modified_gmt":"2026-07-02T19:00:00","slug":"abl-diagnostics-approval-of-dividend-distribution-for-fiscal-year-2025","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=30144","title":{"rendered":"ABL Diagnostics \u2013 Approval of Dividend Distribution for Fiscal Year 2025"},"content":{"rendered":"<p>WOIPPY, France--(BUSINESS WIRE)--Regulatory News:<\/p><p>\nAt the Annual General Meeting of ABL Diagnostics (Paris:ABLD) held on Tuesday, June 30, 2026, at 11:00 a.m., shareholders approved all resolutions submitted for their vote, including the payment of a dividend of \u20ac0.11 per share for the 2025 fiscal year (compared with \u20ac0.05 per share for the 2024 fiscal year), reflecting the Company's improved results and strong financial position.<\/p><p>\nThe dividend will be ex-dividend on July 3, 2026, and will be paid on July 7, 2026.<\/p><p>\n<b>About ABL Diagnostics (ABLD)<\/b><\/p><p>\nABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:<\/p><ul class=\"bwlistdisc\">\n<li>\nMolecular polymerase chain reaction (PCR) detection \u2013 UltraGene, and<\/li>\n<li>\nGenotyping by DNA sequencing \u2013 DeepChek\u00ae.<\/li>\n<\/ul><p>\nABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.<\/p><p>\nABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.<\/p><p>\n<b>An expanding portfolio of microbiology products:<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nHIV \u2013 Drug resistance testing, including a whole genome kit.<\/li>\n<li>\nSARS-CoV-2, Tuberculosis, Hepatitis B and C \u2013 Advanced Detection Solutions.<\/li>\n<li>\nMicrobiome and taxonomy \u2013 16s\/18s RNA-based analyses.<\/li>\n<li>\nOther viral and bacterial targets \u2013 Comprehensive molecular assays.<\/li>\n<\/ul><p>\n<b>Integrated Solutions<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nReal-time syndromic PCR tests<\/li>\n<li>\nNadis\u00ae \u2013 Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.<\/li>\n<li>\nMediaChek\u00ae \u2013 Clinical Sample Collection Kits.<\/li>\n<\/ul><p>\nABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD \u2013 ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>ABL Diagnostics SA<\/b><br\/>Soci\u00e9t\u00e9 anonyme au capital de 1 611 465,60 euros\n<br\/>Headquarters : 72C route de Thionville - 57140 WOIPPY\n<br\/>552 064 933 R.C.S. METZ<\/p><p>\nTel : +33 (0)7 83 64 68 50\n<br\/>Email : <a  href=\"mailto:info@abldiagnostics.com\" rel=\"nofollow\" shape=\"rect\">info@abldiagnostics.com<\/a><br\/><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.abldiagnostics.com%2F&amp;esheet=54564364&amp;newsitemid=20260702954947&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.abldiagnostics.com%2F&amp;index=1&amp;md5=58d6f0ea9816d851e6db35a69cf7ec5f\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.abldiagnostics.com\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>WOIPPY, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:<br \/>\nAt the Annual General Meeting of ABL Diagnostics (Paris:ABLD) held on Tuesday, June 30, 2026, at 11:00 a.m., shareholders approved all resolutions submitted for their vote, including the payment of a di&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-30144","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/30144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30144"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/30144\/revisions"}],"predecessor-version":[{"id":30145,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/30144\/revisions\/30145"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}